NEXT GENERATION ONCOLYTIC IMMUNOTHERAPY NEXT-GENERATION ONCOLYTIC IMMUNOTHERAPY 37th Annual JPMorgan Healthcare Conference Safe harbor 2 Any statements contained herein that are not statements of historical facts may be deemed to be forwardlooking statements which are subject to risks and uncertainties. Accordingly, actual outcomes or results may differ materially from those indicated in these statements for many reasons, including, without limitation, risks associated with our collaborations, our clinical ...